Skip to content
SHOP
  • Home
  • About
  • Science
  • Pipeline
  • News
  • Contact
  • Home
  • About
  • Science
  • Pipeline
  • News
  • Contact
SHOP

News

BioVinc Research Featured as Cover Story in JBMR Plus

March 12, 2026

BioVinc Presentation in 2024 ASBMR Meeting

September 17, 2024

BioVinc Presentation in 2024 ARI Orthopaedics Conference – Orthopaedic Infection

June 10, 2024

BioVinc Presentations in 2023 24th ICPC Meeting

November 10, 2023

BioVinc Presentations in 2023 ASBMR Meeting

October 10, 2023

BioVinc Secures Multi-Million Dollar SBIR Fast-Track Grant from NIH/NIAID to Advance Treatment for Infected Fractures

March 3, 2023

BioVinc Presentation in 2023 ORS Meeting

February 2, 2023

BioVinc Presentation in 2022 ASBMR Meeting

September 8, 2022

BioVinc Presentation in SNMMI 2022 Annual Meeting

June 8, 2022
Previous Page1 Page2 Page3 Next

BioVinc (BV) has pioneered a groundbreaking skeletal-targeted therapy for life-threatening orthopedic infections and osteomyelitis. This innovation makes it possible to eradicate biofilms, including the previously untreatable MRSA on infected implants—offering new hope to prevent amputation and save lives.

Linkedin-in Youtube

BioVinc Data Room

We welcome investors to review our recent OsteoFloxacin™ data and trial results.

Request Access

LINKS

  • About Us
  • Our Science
  • Pipeline
  • News

CONTACT US

2265 E. Foothill Blvd.
Pasadena, CA 91107 USA

+1 (310) 730-5609

info@biovinc.com

©2026 BioVinc, LLC. All rights reserved.
  • Privacy Policy
  • Terms & Conditions
Biotech Website Design
stellar biotech design